Capricor Therapeutics (CAPR) CFO Bergmann Buys $77K of Stock
Anthony Bergmann purchased 24,100 shares of Capricor Therapeutics, valued at $76,638, on June 25, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Anthony Bergmann, CHIEF FINANCIAL OFFICER at Capricor Therapeutics, Inc. ($CAPR), bought 24,100 shares at an average price of $3.18, worth about $76,638, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CAPR is down 23.6% after 1 week, down 77.0% after 1 month and down 77.9% to date (from the $30.40 close on Jun 25, 2026).
CAPR
Capricor Therapeutics, Inc.
Key Points
- On June 25, 2026, CFO Anthony Bergmann bought 24,100 shares of Capricor Therapeutics for a total of $76,638, at a price of $3.18 each.
- The stock is currently trading at $23.80, significantly higher than its 52-week low of $2.96, and has a target mean price of $27.00 from analysts.
- Capricor Therapeutics, which focuses on therapies for Duchenne muscular dystrophy, has seen recent upgrades from multiple analysts, reflecting growing interest.
Get $CAPR trade alerts by text
We text you when insiders, Congress or big funds trade $CAPR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Capricor Therapeutics, Inc. alert may contain errors. Disclosures
CFO Anthony Bergmann Expands Stake in Capricor Therapeutics
On June 25, 2026, Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc. (NasdaqGS: CAPR), bought 24,100 shares for about $76,638 at a price of $3.18 each. This purchase comes at a time when the stock is trading at $23.80, indicating a significant increase from its 52-week low of $2.96.
What Changed in Bergmann's Position
Bergmann's recent buy adds to his existing holdings, increasing his stake in Capricor Therapeutics. This purchase marks a notable commitment to the company, especially given the recent volatility in its stock price. The total number of shares he holds is now 24,100, reflecting his ongoing confidence in the company's future.
Institutional Interest in Capricor
There are no recent changes reported from other institutional investors regarding Capricor Therapeutics. However, Bergmann's buy is particularly interesting given the recent market activity surrounding the stock, which has attracted attention from analysts and investors alike.
Stock Performance and Market Context
Currently, Capricor Therapeutics trades at $23.80, which is a considerable gain from its 52-week low of $2.96. The stock has been volatile, with analysts setting a target mean price of $27.00. This suggests that there may be more upside potential, especially as the company continues to develop its pipeline of therapies.
Insider Buying and Selling at Capricor Therapeutics, Inc.
On the same day as Bergmann's purchase, Karen Krasney, the Executive Vice President and General Counsel, sold 24,100 shares. This action, alongside Bergmann's buy, reflects a mix of insider sentiment at the company. Additionally, Krasney bought 400 shares at the same price of $3.18 on June 24, 2026, showing her continued investment in the firm.
Analysts Set New Price Targets
Capricor Therapeutics has received several recent upgrades from analysts. On September 14, 2026, B. Riley Securities upgraded the stock to a Buy rating with a target price of $21. Piper Sandler also upgraded its rating to Overweight with a target of $25 on September 1, 2026. These upgrades suggest that analysts are optimistic about the company's prospects.
What Capricor Therapeutics, Inc. Does
Capricor Therapeutics is a clinical-stage biotechnology firm based in San Diego, California. The company focuses on developing innovative therapies for Duchenne muscular dystrophy and other serious diseases. Its lead product candidate is currently in a phase 3 clinical trial, highlighting its commitment to addressing unmet medical needs.
What’s Next for Capricor
Investors will be watching for further developments from Capricor Therapeutics, especially with its next earnings report scheduled for November 10, 2026. The recent insider transactions and analyst upgrades will also be of interest as they may indicate future performance. Remember that insider trades reflect past positions and may not indicate current holdings.
Related Filing Alerts
Source: Anthony Bergmann's Form 4 filing on $CAPR (Jun 25, 2026). Find the original filing: CAPR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts